Genmab A/S (NASDAQ:GMAB) Stock Price Expected to Rise, HC Wainwright Analyst Says

Genmab A/S (NASDAQ:GMAB) had its target price boosted by equities researchers at HC Wainwright from $35.00 to $36.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 54.44% from the stock’s current price. HC Wainwright also issued estimates for Genmab A/S’s Q1 2026 earnings at $0.34 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.75 EPS and FY2026 earnings at $2.38 EPS.

GMAB has been the subject of several other reports. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Monday, July 28th. Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, July 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and an average price target of $37.60.

Genmab A/S Stock Up 1.4%

Shares of GMAB stock opened at $23.31 on Friday. The firm has a 50 day moving average price of $21.80 and a two-hundred day moving average price of $20.93. The company has a market capitalization of $14.95 billion, a PE ratio of 11.71, a price-to-earnings-growth ratio of 6.85 and a beta of 0.95. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $27.94.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. As a group, research analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after purchasing an additional 1,464 shares during the period. CWM LLC raised its holdings in shares of Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after purchasing an additional 1,070 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 124.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after purchasing an additional 1,174 shares during the period. Finally, AlphaCore Capital LLC acquired a new position in shares of Genmab A/S during the second quarter valued at about $44,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.